Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus FLUXID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus FLUXID.
DEXILANT vs FLUXID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
FLUXID is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin availability in the synaptic cleft.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
1-2 g IV every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
Terminal half-life: 12 hours (range 10–14 hours). In renal impairment (CrCl <30 mL/min), half-life prolonged to 24–36 hours; dose adjustment required.
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor